Contents

Bimekizumab

Bimekizumab, sold under the brand name Bimzelx, is a humanized anti-IL17A, anti-IL-17F, and anti-IL17AF monoclonal antibody^[6][7] that is used to treat plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and ankylosing spondylitis.^[6]

The most common side effects include upper respiratory tract infections (nose and throat infection) and oral candidiasis (thrush, a fungal infection in the mouth or throat).^[6] Injection site reactions were also common, reported in 3% of subjects.^[8]

Bimekizumab was approved for medical use in the European Union in August 2021,^[6][9][10] and in the United States in October 2023.^[11][12]

In the EU, bimekizumab is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, non-radiographic axial spondyloarthritis, and active ankylosing spondylitis.^[6]

Bimekizumab is being developed by Belgian pharmaceutical company UCB.^{[citation needed]}

Bimekizumab is the international nonproprietary name (INN).^[13]

Phase III trials have demonstrated that bimekizumab is superior to not only adalimumab^[14] but also secukinumab^[15] and ustekinumab^[16] for the treatment of plaque psoriasis.